22 Apr 2024 • The initiation of SGLT2 inhibitors in patients with type 2 diabetes and a history of PCI was significantly associated with a reduced risk of cardiorenal consequences and mortality, irrespective of time since the last PCI.

Compared to DPP-4 inhibitors, SGLT2 inhibitor initiation exhibited significant reductions in composite repeat revascularization, myocardial infarction, stroke, heart failure (HF), all-cause death, and end-stage renal disease (ESRD).

Importantly, these effects persisted regardless of the timing of prior PCI, suggesting a consistent and profound impact of SGLT2 inhibitors on cardiorenal outcomes and mortality in diabetic patients with a history of PCI.

Source: Diabetes, Obesity & Metabolism | Read full story